trending Market Intelligence /marketintelligence/en/news-insights/trending/XrG7sreKViIB2h9wkZmoSw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Stemline Therapeutics plans common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Stemline Therapeutics plans common stock offering

Stemline Therapeutics Inc. plans to sell 6,600,000 common shares through an underwritten public offering.

The New York-based cancer drug developer expects to grant underwriters a 30-day option to buy up to 990,000 additional common shares.

Net proceeds will be used on commercial activities for Elzonris, Stemline Therapeutics' treatment for blastic plasmacytoid dendritic cell neoplasm, a rare blood disease. Funds will also go toward clinical trials, including those for additional indications of Elzonris, research and development activities, potential acquisitions and in-licensing, as well as other general corporate purposes.

J.P. Morgan Securities LLC is acting as book-running manager for the offering.